Nabil S. Andrawis, M.D., Ph.D.

Dr. Andrawis received his medical degree from Ain Shams University Medical School in Cairo in 1976 and his PhD degree from Wayne State University in Detroit in 1988. He then received training at Harvard and Brown Universities for 6 years. He moved to the Washington area in 1994 to become an Assistant Professor in the Department of Medicine at Georgetown University.

Over the years, he has received many awards and has published numerous scientific articles in the medical field. He is certified by the American Board of Internal Medicine and is licensed to practice medicine in Virginia and Washington, D.C.

Click for more details:
Education
Clinical Research Experience
Awards and Honors
License and Certifications
Personal
Publications

Education

Undergraduate, Graduate, and Medical Education

1976 Medical Degree (M.D.)
Ain Shams University Medical School, Cairo, Egypt

1980 Master's Degree (M.S.)
Zgazig University Medical School, Zgazig, Egypt

1988 Ph.D. Degree in Pathology and Cell Biology
Wayne State University Medical School, Detroit, MI

Internship and Residencies

1976-1977 Intern in Medicine
Ain Shams University Hospital, Cairo, Egypt

1978-1983 Instructor/Assistant Professor, Forensic Medicine and Toxicology
Zgazig University Hospital, Zgazig, Egypt

1983-1984 Clinical Fellowship
Medical Examiner Office of Wayne County, Detroit, MI

1991-1994 Internship and Residency in Internal Medicine
Memorial Hospital of Rhode Island, Brown University, Pawtucket, RI

Research Fellowships

1983-1985 Peace Fellowship
offered by US government to outstanding Egyptian Investigators

1985-1988 Research Associate
Wayne State University, Detroit, MI

1988-1990 Research Fellowship, Division of Vascular Medicine
Molecular & Cellular Vascular Research Lab, Brigham & Women's Hospital
Harvard Medical School, Boston, MA

1990-1994 Research Fellowship, Program in Clinical Pharmacology
Brown University, Department of Medicine, Providence, RI

Clinical Research Experience

For more information on our clinical trials >>

Principal investigator in multiple clinical trials. Most recent ones are:

• POWER Trial.
• INVEST Trial (University of Florida). An international, randomized, controlled clinical trial comparing a c calcium antagonist treatment strategy (verapamil SR) with a non-calcium antagonist treatment strategy (atenolol) for control of hypertension in a primary care coronary artery disease patient population. Sponsor: Knoll AG BASF Pharma. Six patients enrolled. (2000-2002).
• TREAT Trial. Randomized, Open-Label, Multicenter Trial of the Safety and Effectiveness of Oral Telithromycin (Ketek) and Amoxicillin/Clavulanic Acid (Augmentin) in Outpatients with Respiratory Tract Infections in Usual Care Settings, Protocol # HMR3647A/3014, Sponsor: Aventis Pharmaceuticals. Twenty patients enrolled. (2001-2002).
• JUPITER Trial (Astra Zeneca). A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin (CRESTOR�) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated levels of C-Reactive Protein. Eighteen patients enrolled. (2003-Present)
• IRIS Trial (Astra Zeneca). A 6-week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolemia in South Asian Subjects. Eleven patients enrolled. (2003-2005)
• STARSHIP STUDY (AstraZeneca). A 6-week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolemia in Hispanic Subjects. Nine patients enrolled. (2003-2005)
• B3A20005 (GlaxoSmithKline). A 12-Week, Parallel-Group, Double-Bline, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of GW427353B at 10mg, 25mg, 50mg and 100mg, Administered Orally, Once Daily, as Monotherapy in Subjects with Type 2 Diabetes Mellitus. Ten patients enrolled. (2004-2005)
• SB-275833/030-Studies 030A and 030B (GlaxoSmithKline). Two Identical Double-blind, Double-dummy, Multicenter, Comparative Phase III Studies of the Safety and Efficacy of Topical 1% SB275833, Applied Twice Daily, versus Oral Cephalexin, 500 mg in Adults, or 12.5 mg/kg (250mg/5ml) in Children, Twice Daily, in the Treatment of Uncomplicated Secondarily Infected Traumatic Lesions. Seventeen patients enrolled. (2004-2005)
• 20010184 (Amgen) Trial to Reduce Cardiovascular Events with Aranesp� Therapy. (Sept 2004-Present)
• 20040180 (Amgen) An Open-Label, Single-Arm Study to Assess the safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease (Dec 2004-Present)
• D6160C00029 Gallant 5 (AstraZeneca) A 52-Week Randomized, Double Blind, Parallel-Group, Multi-Centre, Active Controlled (Metformin) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered to Patients with Type 2 Diabetes. (Mar 2005-Present)
• DPB 100925 (GlaxoSmithKline) A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of GW823093 (2.5mg, 7.5mg, 15mg, 30mg, 45mg), Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus followed by a 12-week Active Treatment Extension. (Apr 2005-Present)
• CS8663-A-U301 (Sankyo) A Randomized, Double-Blind, Placebo-Controlled Factorial Study Evaluating the Efficacy and Safety of Co-Administration of Olmesartan Medoxomil plus Amlodipine Compared to Monotherapy in Patients with Mild to Severe Hypertension. (Apr 2005-Present)

Awards and Honors

1970-1976 Ain Shams University Undergraduate Scholarship

1976 M.D. degree graded "VERY GOOD WITH HONOR" Zgazig University Postgraduate Scholarship

1983-1985 Peace Fellowship offered by US government to outstanding Egyptian investigators

1985-1988 Wayne State University Graduate Scholarship

1988 Wayne Sate University Grant for dissertation research

1991 Young Investigator travel award recipient from the American Society for Pharmacology and Experimental Therapeutics

1992 Dr. Henry Christian Memorial Award for Excellence in Research Awarded by American Federation for Clinical Research.

1992 American Heart Association Fellowship Grant, Providence, RI

1991-1993 Pharmaceutical Manufacturers Association Fellowship "Careers In Clinical Pharmacology"

1993-1995 Merck/American Federation for Aging Research Fellowship in Geriatric Clinical Pharmacology

1994-1995 Graduate School Georgetown University Research Starter Grant

1994-1995 Department of Medicine Georgetown University Research Starter Grant

1995-1997 American Heart Association, D.C. affiliate, Grant-In-Aid

1996-1999 Pharmaceutical Manufacturers Association Faculty Development Award

License and Certifications

1991 ECFMG Certification

1994 Washington DC Medical License

1995 Commonwealth of Virginia Medical License

1996 Board Certified - American Board of Internal Medicine

1999 Civil Surgeon - Designated by Immigration and Naturalization Services to perform physical examinations for immigrants

2001 Aviation Medical Examiner - Designated by the Federal Aviation Administration to perform physical examinations for class II and III pilots

Personal

Dr. Andrawis is married to his lovely wife Dr. Nashwa Gabra. They have three wonderful children, 18, 16, and 9 and live in Fairfax Station. The doctors are originally from Egypt and have resided in the USA for the past 20 years. They are fluent in English and Arabic. Both are active members of St. Mark Coptic Orthodox Church of Washington, DC.

Publications

Published Peer Reviewed Journal Articles:

1. Andrawis N.S., Kou T.H., Giacomelli F., Wiener J. Altered calcium regulation in the cardiac plasma membrane in experimental renal hypertension. J. Mol. Cell Cardiol. 20:625-634,1988

2. Andrawis N.S., Pratt R.E., Brock T.A., Dzau V.J. Mas oncogene receptor coupling and peptide specificity in Balb 3T3 adn vascular smooth musche cells. Am.J. Med. Sci. 302:329-334,1991.

3. Andrawis N.S., Dzau V.J., Pratt R.E. Autocrine stumulation of mas oncogene leads to altered growth control. Cell Biol. Int. Rep. 16:547-555, 1992.

4. Andrawis N., Craft N., Abernethy D.R. Calcium antagonists block angiotensin II- mediated vasoconstrictors in humans. Comparison with their effect on phenylephrine-induced vasoconstriction, J. Pharmacol. Exp. Ther. 261:879-884,1992.

5. Andrawis N.S., Abernethy D.R. Verapamil Blocks basal and angiotensin II-induced RNA synthesis of rat aortic vascular smooth muscle cells. Biophys. Biochem. Res. Comm. 183:767-773, 1992.

6. Andrawis N.S., Gilligan J., Abernethy D.R. Endothelin-I mediated vasoconstriction: Specific blockade by verapamil. Clin. Pharm. Ther. 52:583-589, 1992.

7. Andrawis N.S., Abernethy D.R. Dffect of calcium antagonists on RNA synthesis of NIH 3T3 cells. Am.J. Med. Sci. 306:137-140, 1993.

8. Abernethy D.R., Wainer I.W., Longstreth J.A., Andrawis N.S. Stereoselective Verapamil disposition and dynamics in aging during racemic verapamil administration. J. Pharmacol. Exp. Ther. 266(2):904-911, 1993.

9. Andrawis N.S., Ruley E.H., Abernethy D.R. Angiotensin II regulates human vascular smooth muscle a-action gene expression. Biochem. Biophys. Res. Comm.196:962-969, 1993.

10. Abernethy D.R., Andrawis N.S. Critical drug interactions: A guide to important examples. Drug Theraphy 23:15-27, 1993.

11. DePetrillo P.B., Abernethy D.R., Wainer I.W., Andrawis N.S. Verapamil decreases lymphocyte protein kinase C activity in humans. Clin. Pharm. Ther. 55:44-49, 1994.

12. Abernethy D.R., Andrawis N.S. Critical drug interactions: A guide to important examples. Physician Assistant 18:15-21, 1994.

13. Abernethy D.R., Laurie N., Andrawis N.S. Local angiotensin converting enzyme inhibition blunts endothelin-1 induced increase in forearm vascular resistance. Clin. Pharm. Ther, 58:328-34, 1995.

14. Andrawis N.S., Wang E., and Abernethy D.R. Endothelin-1 induces increase of total protein synthesis and expression of smooth muscle a-actin gene in vascular smooth muscle cells. Life Science 59(7): 523-528, 1996.

15. Shi S-J, Preuss H. G., Abernethy D. R., Li Y., Li X., Jarrell T., and Andrawis N.S. Elevated blood pressure in spontaneously hypertensive rats consuming a high sucrose diet is associated with elevated angiotensin II and is reversed by vanadium. Journal of Hypertension. 15(8):857-862, August 1997.

16. Liu, X.K., Abernethy, D.R. and Andrawis, N.S.: Nitric oxide inhibits Oct-1 DNA binding activity in cultured vascular smooth muscle cells. Life Sci 62: 739-49, 1998.

17. Andrawis NS, Battle MM, Klamerus KJ, Burghart PH, Neefe L, Weinryb I, Mayer P, Abernethy DR: A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension. J Clin Pharmacol 2000; 40: 231-241.

18. Andrawis N, Jones DS, Abernethy DR: Aging is associated with endothelial dysfunction in the human forearm vasculature. J Am Geriatr Soc 2000; 48: 193-198.

19. Jones DS, Andrawis NS, Abernethy DR: Impaired endothelial-dependent forearm vascular relaxation in black Americans. Clin Pharmacol Ther 1999; 65: 408-412.

Abstracts:

1. Andrawis N.S., Kuo T.H., Giancomelli F., Wiener J. Calcium antagonist receptors in cardiac sarcolemma of hypertensive rats: Altered binding characteristics. Federation Proc. 46:1411, 1987.

2. Andrawis N.S., Stevension L.F., Pratt R.E., Dzau V.J. Does the mas oncogene encode an angiotensin receptor? Evidence from stably transfected fibroblast and smooth muscle cells. UCLA Symposia; Molecular Biology of the Cardionvascular System, April 10-16, 1989, Keystone, Colorado.

3. Andrawis N.S., Stevenson L.F., Pratt R.E., Dzau V.J. Autocrine angiotensin stimulation of mas oncogene leads to altered growth control. Hypertension 14:340, 1989.

4. Andrawis N.S., Dzau V.J., Pratt R.E. Autocrine Stimulation of the mas oncogene modulates the response of 3T3 cells to substance P. 13th Scientific Meeting of the international Society of Hypertension, Montreal, Canada. P5 25:s101�, 1990.

5. Andrawis N.S., Dzau V.J., Pratt R.E. Autocrine stimulation of mas oncogene modulates the response or 3T3 cells to substance P. Clinical Research 38(2):242A, 1990.

6. Andrawis N., Tsai S.-W., Abernethy D.R. alpha-actin expression is suppredded in aging multiple passage cultured rat aortic vascular smooth muscle cells. Clinical Research 39(2):228A, 1991.

7. Andrawis N.S., Abernethy D.R. Verapamil blocks basal and angiotensin II-induced synthesis of actin mRNA. The Pharmacologist 33(3):223, 1991.

8. Abernethy D.R., Andrawis N.S. Increased angiotensin II responsiveness of vascular smooth muscle cells of aged Fischer 344 rats. The Pharmacologist 33(3):223, 1991.

9. Craft N., Andrawis N.S., Abernethy D.R. Comparison of the effets of calcium antagonists on angiotensin II and phenylephrine-induced vasoconstriction. The Pharmacologist 33(3):204,1991.

10. Andrawis N.S., Craft N., Abernethy D.R. Differential alpha-adrenergic blockade by calcium antagonists. J. Clin. Pharmalo. 31:841, 1991.

11. Abernethy D.R., Craft N., Andrawis N. Diltiazem blocks angiotensin II-mediated vasoconstriction in vivo. Clin Pharmac Therap 49(2):142,1991.

12. Andrawis N., Craft N., Abernethy D.R. Verapamil blocks angiotensin II-mediated vascular responses. Clin Pharmac Therap 49(2):201, 1991.

13. Andrawis N.S., Craft N., Abernethy D.R. Vascular angiotensin blockade by calcium antagonists. FASEB J (4):A841, 1991.

14. Andrawis N.S., Krochmal R., Abernethy D.R. Evidence for a calcium channel-independent induced decrease in cellular hypertrophy by calcium antagonists. Clin. Pharmacol. Ther. 51:143, 1992.

15. Andrawis N.S., Abernethy D.R. Growth inhibition of verapamil (VEP) on vascular smooth muscle (VSMC): Blockade of angiotensin II (AII) effect. Clin. Pharmacol. Ther. 51:143, 1992.

16. Abernethy Dr., Tsai S.-W., Andrawis N.S. Acute and chronic responses to Angiotensin II in aging. Clin. Pharmacol. Ther. 51:176, 1992.

17. Abernethy D.R., Craft N., Andrawis N.S. Calcium antagonists (CA): a-adrenergic blockade is not a common characteristic. Clin. Pharmacol. Ther. 51:193,1992.

18. Tsai S.-W., Andrawis N.S., Abernethy D.R. Verapamil Blocks endothelin-I (ET-I) mediated vascular effects. The FASEB J. 6:A1004, 1992.

19. Andrawis N.S., Abernethy D.R. Regualtion of a-actin vascular smooth muscle gene calcium antagonists. The FASEB J. 6A:1867,1992.

20. Andrawis N.S., Abernethy D.R. Angiotensin II and verapamil activate positive and negative regulatory elements in the human vascular smooth muscle a-actin gene. Clin. Res. 40:326A, 1992.

21. Abernethy Dr., Andrawis N.S. Verapamil (VER) blocks fetal calf serum stimulated RNA synthesis in NIH 3T3 fibrobasts. The FASEB J. 6:A1869, 1992.

22. Adrawis N., Abernethy D.R. Calcium antagonists block angiotensin II-mediated vasoconstrictors in humans. Comparison with their effect on phenylephrine-induced vasoconstriction. J. Pharmacol. Expt. Therap. 261:879-884,1992.

23. Andrawis N.S., Abernethy D.R. In vivo and in vitro evidence for vascular angiotensin II blockade by calcium antagonists. American College of Physicians-Rhode Island Chapter Meeting, Providence, RI, April 1992.

24. DePetrillo P.B., Andrawis N.S., Abernethy D.R. Verapamil decreases lymphocyte protein kinase C activity in humans. The Pharmacologist 34:139, 1992.

25. Andrawis N.S., Gilligan J., Abernethy D.R. Verapamil selectively blocks Endothelin-I mediated vasoconstriction in humans. The Pharmacologist 34:148, 1992.

26. Andrawis N.S., McCoy C. Isoniazid associated rhabdomyolysis. American College of Physicians-Rhode Island Chapter, Providence, RI, March 1993.

27. Andrawis N.S., Gaudet E.E., Heller G. V. Chronic elevation of CK-MB Isoenzymes in a male patient. American College of Physicians-Rhode Island Chapter, Providence, RI, March 1993.

28. Craft N., Andrawis N.S., Abernethy D.R. Elevated basal and endothelin-I stimulated a-smooth muscle actin mRNA expression in an aged vascular smooth muscle model. Clin. Res. 41(2):126A, 1993.

29. Andrawis N.S., T sai S.-W., Abernethy D.R. Angiotensin II and verapamil reguate expression of vascular cytoskeletal proteins. Clin. Pharmacol. Ther. 53(2):205, 1993.

30. Andrawis N.S., Abernethy D.R. Endothelin-1 regulates total protein synthesis and expression of cytoskeletal proteins. In vascular smooth muscle cell. Clin. Pharmacol. Ther. 55(2):151.

31. Abernethy DR., Laurie N., Andrawis N.S. Local angiotensin converting enzyme inhibition blunts endothelin-1 induced increase in forearm vascular resistance. Clin. Pharmacol. Ther. 55(2):151.

32. Andrawis N.S., Wang E., Gabra N., Abernethy D.R. Vascular smooth muscle cell cytoskeletal protein regulation by endothelin-1. The FASEB J. 8:A555, 1994.

33. X-K Liu, D.R. Abernethy, Y. Li, O. Shahine and N.S. Andrawis. Nitric oxide directly inhibits Oct1 DNA binding activity in cultured vascular smooth muscle cells Clin. Pharmacol. Ther, 59:174, 1996.

34. N.S. Andrawis, J. Hackenburck, Y. Li, and DR. Abernethy. Angiotensin II and endothelin-1 induction of myc and AP-1 transcription factor binding activity in vascular smooth muscle cells is reversed by nitric oxide. Clin. Pharmacol. Ther, 59:176, 1996

35. D. R. Abernethy, L. Kelly and N.S. Andrawis. Endothelin-1 (ET-1) induces prolonged AP-1 transcription factor DNA binding activity in vascular smooth muscle cells isolated from aged Fischer 344 rats. The FASEB J. 10 (3), A558, 1996

36. S. R. Donahue, N.S. Andrawis, and D. R. Abernethy. Enzymatically oxidized LDL Increases DNA synthesis and induces AP-1 DNA binding activity. The FASEB J. 10 (3), A271, 1996

37. Y. Li, D. Rabernethy, and N.S. Andrawis. Nitric oxide directly inhibits vascular smooth muscle AP-1 DNA binding activity. The FASEB J. 10 (3), A444, 1996

38. X-K Liu, D. R. Abernethy, Y Li, O. Shahine and N. S. Andrawis. Nitric oxide (NO) directly inhibits Oct1 DNA binding activity in cultured vascular smooth cells (VSMCs). The FASEB J. 10 (3), A271, 1996

39. X-K Liu, D. R. Abernethy, Y. Li, O. Shahine and N. S. Andrawis. In vitro and in vivo evidence for inhibition of Oct1 DNA binding activity in cultured vascular smooth muscle cells (VSMCs). The FASEB J. 10 (3), A342, 1996

40. N. S. Andrawis, K. Sandgerg, W. Zheng and , D. R. Abernethy, Vascular smooth muscle cells (VSMCs) from aged Fischer 344 rats have increased angiotensin II (AII)-induced calcium 45 uptake and AII binding. The FASEB J. 10 (3), A769, 1996

41. Shi S-J, Preuss H. G., Abernethy D. R., Li Y., Li X., Jarrell T., and Adrawis N. S. Elevated blood pressure in spontaneously hypertensive rats consuming a high sucrose diet is associated with elevated angiotensin II and is reversed by vanadium. Clin. Pharmacol. Ther, 61:207, 1997

42. Shi S-J, Abernethy DR, Wilcox CS, Welch Wj, Li X, Moussa M, and Andrawis NS. Effects of sodium balance on vascular renin and angiotensinogen mRNA expression in rats. The Pharmacologist March, 1997

Invited papers, Ph.D. thesis, and book chapters:

1. Andrawis N.S. Doctor of Philosophy Dissertation Research on �Altered calcium regulation in cardiac plasma membrane in experimental renal hypertension� Wayne State University, Detroit, MI, 1988.

2. Abernethy D.R., Andrawis N. Hypertension in the elderly. In PRACTICE OF GERIATRICS, 2nd ed. (E.Calkins, A.B. Ford, and P.R. Katz, Eds.) W.B Saunders Company, Philadelphia, PA, 1992, Chpter 45, pp 454-461.

3. Andrawis N.S. Left ventricular function and perfusion in the aging patient with hypertension. Cardiovascular Update, January 1992.

4. Abenethy D.R., Andrawis N.S. Stereoisomeric drugs in therapeutics: clinical perpectives. IN DRUG STEREOCHEMISTRY: ANALYTICAL METHODS AND PHARMACOLOGY, 2nd ed. (Wainer I. W., ed.),, Marcel Dekker, Inc. New York, 1993, Chapter 15, pp 3859397.

5. Abernethy D.R., and Andrawis N.S. Pharmacodynamics of calcium antagonist drugs. In PHARMACODYNAMICS AND DRUG DEVELOPMENT: PRESPECTIVES IN CLINICAL PHARMACOLOGY. (N.R. Cutler, J.J. Sramek and P. K. Narang, ed), John Wiley & Sons Ltd, 1994, Capter 14, pp 253-266.

Burke Internal Medicine, Inc.
5631 Burke Centre Parkway
Suite A
Burke, VA 22015
(Near Fairfax, Virginia)
Tel: 703.250.5171
Fax: 703.250.5170
MAP & DIRECTIONS >>

Clinical Trials/Medical Research | Immigration Physicals | Flight Physicals | Hair Removal

Primary Care and Clinical Research Center in DC/Fairfax Area

Legal Notice | General Website Disclaimer

Website errors? Contact the Healthcommunities.com webmaster.
Please provide the website address in your message.
(Messages sent to Healthcommunities.com will not reach the practice.)

© 1998 - 2008 Healthcommunities.com, Inc. All rights reserved.

Medical Website Design by Healthcommunities.com

Site hosted by Creative Mesh.